Approved indications (U.S.):

• Adjunct to prevent rejection in kidney (renal) transplantation, usually in combination with other immunosuppressive drugs.
• Treatment of active rheumatoid arthritis in adults to reduce signs and symptoms, often when other disease-modifying drugs are not adequate or not tolerated.

Common off-label uses and evidence:

• Inflammatory bowel disease (Crohn’s disease and ulcerative colitis) as a steroid-sparing maintenance therapy; supported by multiple randomized trials and guideline recommendations.
• Autoimmune hepatitis and some other autoimmune liver diseases; generally good evidence from cohort studies and guidelines.
• Various autoimmune and inflammatory disorders (e.g., certain blistering skin diseases, severe eczema/atopic dermatitis, systemic lupus, vasculitis, myasthenia gravis), where evidence ranges from small trials to case series and expert consensus.

Efficacy expectations:

• Kidney transplant: reduces the rate of acute rejection and helps maintain graft function, though newer agents (e.g., mycophenolate) are often preferred; benefit depends on the overall immunosuppressive regimen.
• Rheumatoid arthritis and many autoimmune diseases: improvement usually begins after 6–8 weeks, with maximal benefit often by 3–6 months; typical outcomes are reduced pain, swelling, and need for steroids.
• Effectiveness may be lower or slower than some biologic agents, but azathioprine can be useful when biologics are not appropriate or available.

Typical dosing (oral tablets):

• Kidney transplant (adult): usually 3–5 mg/kg once daily starting at or just before transplantation, then reduced to a maintenance dose of about 1–3 mg/kg once daily, individualized to balance rejection risk and toxicity.
• Rheumatoid arthritis (adult): typically started at about 1 mg/kg once daily (often 50–100 mg per day) and may be increased gradually up to about 2–2.5 mg/kg per day if needed and tolerated.
• Doses are adjusted for kidney or liver impairment and for patients with reduced TPMT or NUDT15 activity.

How to take the medicine:

• Swallow tablets whole with water; taking them after food can lessen stomach upset.
• Take the dose at the same time each day; do not change the dose or stop suddenly without medical advice.
• Regular blood tests (usually frequent at the start, then monthly or as directed) are essential to monitor blood counts and liver function.

Special dosing instructions:

• If you are prescribed allopurinol or another xanthine oxidase inhibitor, your azathioprine dose usually must be reduced to about one‑third to one‑quarter of the usual dose, or an alternative regimen used.
• People with known TPMT or NUDT15 deficiency often require substantial dose reduction or a different medication.

Missed dose and overdose guidance:

• Missed dose: take it as soon as you remember the same day; if it is almost time for the next dose, skip the missed one and resume your regular schedule. Do not double up doses.
• Overdose: seek emergency medical care or contact poison control right away; symptoms may include severe nausea, vomiting, diarrhea, and delayed bone marrow suppression.

Common side effects (usually mild to moderate):

• Gastrointestinal upset (nausea, vomiting, loss of appetite, sometimes diarrhea), especially when starting therapy; often improves if taken after meals or in divided doses.
• Mild fatigue, headache, or general malaise.
• Mild hair thinning or skin rash in some people.
• Infections such as colds or other minor infections may occur more often because of immune suppression.

Serious or less common adverse effects (need urgent medical attention):

• Bone marrow suppression (low white cells, red cells, or platelets) causing fever, sore throat, mouth sores, unusual bruising or bleeding, extreme fatigue, or shortness of breath.
• Serious infections, including opportunistic infections or reactivation of latent infections.
• Liver injury (hepatitis, cholestasis, or very rarely veno-occlusive disease) with symptoms such as jaundice, dark urine, right‑upper‑abdominal pain, or severe fatigue.
• Pancreatitis (sudden severe upper abdominal pain, nausea, vomiting).
• Progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection, signaled by new or worsening weakness, vision changes, speech or balance problems, or confusion.
• Increased risk of cancers, particularly lymphomas and skin cancers, and rare hepatosplenic T‑cell lymphoma (especially in younger patients with IBD on combination immunosuppression).
• Severe allergic or hypersensitivity reactions with high fever, severe stomach upset, rash, muscle aches, and sometimes low blood pressure.

Warnings and precautions:

• Pregnancy: can harm the fetus; in rheumatoid arthritis it should not be used in pregnancy, and in transplant or other life‑threatening conditions it is used only if benefits clearly outweigh risks.
• Breastfeeding: azathioprine and its metabolites appear in breast milk; use is generally not recommended, or requires individualized specialist guidance.
• Children: safety and effectiveness have not been established in pediatric patients on the U.S. label, although it may be used off label under specialist supervision.
• Elderly patients and those with kidney or liver disease, or genetic TPMT/NUDT15 deficiency, have higher risk of bone marrow toxicity and usually require lower doses and closer monitoring.

Comparative safety:

• Compared with many newer biologic agents, azathioprine is inexpensive but carries notable risks of bone marrow suppression, infections, liver injury, and malignancy, especially at higher doses or in transplant regimens with multiple immunosuppressants.

Reporting side effects and staying updated:

• Patients in the United States can report suspected side effects to the FDA’s MedWatch program or to their prescriber or pharmacist, who can submit reports.
• Up‑to‑date safety information is available from the drug’s Medication Guide or prescribing information and from major regulatory and professional society websites.

Major drug and supplement interactions:

• Xanthine oxidase inhibitors (allopurinol, febuxostat): greatly reduce azathioprine breakdown and can cause life‑threatening bone marrow suppression unless the azathioprine dose is markedly reduced; concomitant use with febuxostat is generally avoided.
• Aminosalicylates (sulfasalazine, mesalamine, olsalazine): may inhibit TPMT and increase risk of low blood counts; require closer monitoring.
• Other myelosuppressive drugs (e.g., methotrexate, cotrimoxazole/trimethoprim‑sulfamethoxazole, some chemotherapy): can add to bone marrow toxicity.
• ACE inhibitors: have been associated with severe anemia and leukopenia when combined with azathioprine in some patients.
• Warfarin: azathioprine can reduce warfarin’s anticoagulant effect; INR should be checked more frequently when starting or changing doses.
• Ribavirin: can alter azathioprine metabolism and markedly increase risk of pancytopenia.
• Other immunosuppressants or biologic agents: combination therapy (e.g., with TNF blockers) can increase risks of serious infection and lymphoma and is usually reserved for selected high‑risk cases under specialist care.

Food, alcohol, and vaccines:

• No major food restrictions are required, but alcohol should be limited because both alcohol and azathioprine can affect the liver.
• Live vaccines (e.g., live shingles, measles‑mumps‑rubella, oral typhoid, intranasal flu) are generally avoided during treatment; inactivated vaccines are usually safe but may be less effective.

Conditions and co‑medications requiring caution or avoidance:

• Pre‑existing liver disease, significant kidney dysfunction, or a history of severe bone marrow suppression.
• Known TPMT or NUDT15 deficiency, or a family history of severe thiopurine toxicity.
• Current serious infection or uncontrolled chronic infection.
• History of certain cancers, particularly lymphomas or skin cancers, which may increase with immunosuppression.

Monitoring needs:

• Baseline and periodic complete blood counts (CBC) and liver function tests are essential.
• Consider TPMT and/or NUDT15 testing before starting therapy, especially in populations at higher genetic risk.
• Kidney function and overall immunosuppressive burden should be reviewed regularly, particularly in transplant recipients.

Q: How long does it take for azathioprine to start working?
A: For rheumatoid arthritis and many autoimmune conditions, noticeable improvement often begins after 6–8 weeks, with full benefit sometimes taking 3–6 months.

Q: Will I need regular blood tests while taking azathioprine?
A: Yes, frequent blood tests are needed at the start and then at regular intervals to monitor blood counts and liver function and to adjust the dose safely.

Q: Can I drink alcohol while on azathioprine?
A: Light to moderate alcohol may be allowed for some people, but it should be limited because both alcohol and azathioprine can affect the liver; follow your prescriber’s specific advice.

Q: Is azathioprine safe during pregnancy or breastfeeding?
A: Azathioprine can harm an unborn baby and is generally avoided for rheumatoid arthritis in pregnancy; in transplant or other serious diseases it may be used only when benefits clearly outweigh risks, and breastfeeding usually is not recommended without specialist input.

Q: What should I do if I get a fever or signs of infection while taking azathioprine?
A: Contact your health care provider promptly if you develop fever, chills, sore throat, new cough, or other signs of infection, and do not stop or change your dose on your own unless instructed.

Storage:

• Store azathioprine tablets at room temperature (about 68°F to 77°F / 20°C to 25°C), in a dry place away from excess heat, moisture, and direct light.
• Keep tablets in the original container with the lid tightly closed and out of reach of children and pets.

Handling and disposal:

• Do not crush or split tablets unless your prescriber specifically tells you to; wash hands after handling the medicine.
• Do not throw unused tablets in household trash or flush them down the toilet; use a community drug take-back program or follow pharmacist or local guidance for safe disposal.